Shares of MyoKardia, Inc. (NASDAQ:MYOK) hit a new 52-week high during mid-day trading on Wednesday . The company traded as high as $37.45 and last traded at $37.55, with a volume of 2,178,477 shares. The stock had previously closed at $36.20.

MYOK has been the topic of a number of research analyst reports. BMO Capital Markets reiterated a “buy” rating and set a $45.00 target price on shares of MyoKardia in a research report on Tuesday. ValuEngine upgraded MyoKardia from a “sell” rating to a “hold” rating in a research report on Monday. TheStreet upgraded MyoKardia from a “d+” rating to a “c” rating in a research report on Thursday, July 6th. Zacks Investment Research cut MyoKardia from a “hold” rating to a “sell” rating in a research report on Thursday, May 11th. Finally, Wells Fargo & Company reiterated an “outperform” rating and set a $48.00 target price (up previously from $31.00) on shares of MyoKardia in a research report on Monday. One analyst has rated the stock with a sell rating, one has assigned a hold rating, four have given a buy rating and one has given a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $37.60.

The stock’s market cap is $1.18 billion. The company has a 50 day moving average price of $14.29 and a 200-day moving average price of $13.21.

MyoKardia (NASDAQ:MYOK) last released its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($0.41) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.37) by $0.04. The firm had revenue of $5.60 million during the quarter, compared to analyst estimates of $6.73 million. MyoKardia had a negative net margin of 44.65% and a negative return on equity of 16.63%. MyoKardia’s quarterly revenue was up 60.0% on a year-over-year basis. During the same quarter last year, the firm earned ($0.37) earnings per share. On average, equities analysts forecast that MyoKardia, Inc. will post ($1.64) EPS for the current fiscal year.

In other MyoKardia news, CEO Anastasios Gianakakos sold 4,300 shares of the business’s stock in a transaction dated Friday, August 4th. The shares were sold at an average price of $16.62, for a total value of $71,466.00. Following the transaction, the chief executive officer now directly owns 512,463 shares in the company, valued at $8,517,135.06. The transaction was disclosed in a document filed with the SEC, which is available through this link. 46.10% of the stock is owned by insiders.

Several institutional investors have recently made changes to their positions in the company. Fernwood Investment Management LLC raised its position in shares of MyoKardia by 0.8% in the first quarter. Fernwood Investment Management LLC now owns 43,323 shares of the biotechnology company’s stock worth $570,000 after buying an additional 327 shares during the last quarter. Schwab Charles Investment Management Inc. raised its position in shares of MyoKardia by 5.8% in the first quarter. Schwab Charles Investment Management Inc. now owns 43,680 shares of the biotechnology company’s stock worth $575,000 after buying an additional 2,394 shares during the last quarter. Rhumbline Advisers raised its position in shares of MyoKardia by 45.4% in the second quarter. Rhumbline Advisers now owns 18,489 shares of the biotechnology company’s stock worth $242,000 after buying an additional 5,773 shares during the last quarter. Swiss National Bank raised its position in shares of MyoKardia by 25.7% in the second quarter. Swiss National Bank now owns 31,790 shares of the biotechnology company’s stock worth $416,000 after buying an additional 6,500 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its position in shares of MyoKardia by 11.7% in the second quarter. Bank of New York Mellon Corp now owns 63,208 shares of the biotechnology company’s stock worth $828,000 after buying an additional 6,603 shares during the last quarter. Institutional investors own 47.74% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “MyoKardia, Inc. (NASDAQ:MYOK) Reaches New 1-Year High at $37.45” was originally published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of international copyright & trademark laws. The original version of this piece of content can be accessed at https://www.watchlistnews.com/myokardia-inc-nasdaqmyok-reaches-new-1-year-high-at-37-45/1466045.html.

MyoKardia Company Profile

MyoKardia, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Company is engaged in the business of developing and commercializing therapeutics.

Receive News & Ratings for MyoKardia Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MyoKardia Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.